Mycophenolate Mofetil and Mood Changes in Children with Skin Disorders

详细信息    查看全文

• 作者：Lisa Arkin ; Sreya Talasila and Amy S. Paller
• 刊名：Pediatric Dermatology
• 出版年：2016
• 出版时间：May/June 2016
• 年：2016
• 卷：33
• 期：3
• 页码：e216-e217
• 全文大小：44K
• ISSN：1525-1470

文摘

The Risk Evaluation and Mitigation Strategy program that the U.S. Food and Drug Administration has mandated has intensified the counseling associated with prescribing mycophenolate mofetil (MMF), because of its teratogenicity. In this brief report, two children are described who were prescribed MMF and within weeks developed psychiatric symptoms, with rapid resolution after discontinuation of the medication and no recurrence over 4 years of follow-up. Mood disorders are a rare but possible side effect that should be mentioned when discussing MMF with patients and families. Prompt discontinuation of the drug should lead to reversal of symptoms when the drug is implicated.